Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carbocysteine lysine salt (also known as carbocisteine lysine) is a mucolytic agent primarily developed and marketed by Dompé for the treatment of respiratory disorders characterized by excessive or viscous mucus. It is a salt form of carbocisteine (S-carboxymethyl-L-cysteine) combined with the amino acid L-lysine, a formulation designed to enhance solubility and improve gastric tolerability compared to the base molecule. The drug acts by reducing the viscosity of bronchial secretions through the cleavage of disulfide bonds in mucoproteins, thereby facilitating expectoration and improving airway clearance. It is widely used in the management of chronic obstructive pulmonary disease (COPD), acute and chronic bronchitis, and other upper and lower respiratory tract infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carbocisteine lysine salt.